

## **Adherium awarded contract for sensor and software supply to AstraZeneca clinical study**

**Melbourne, Australia – 24 September 2021:** Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that it has been awarded a contract for supply of the Hailie® solution to an upcoming US-based clinical study by AstraZeneca.

Adherium will be providing a bespoke version of its Hailie® sensor and software to track the usage of the investigational inhaler medications via the study participants' phones. The sensors and software will be supplied for commencement of the study during FY2022, generating approximately US\$650,000 in revenue, and further support services will be supplied over the course of the study's two-year duration.

Rick Legleiter, Adherium's CEO commented "Adherium has a longstanding clinical study supply relationship with AstraZeneca to support the collection of objective clinical trial data using Adherium's Hailie® technology. This is welcome revenue as Adherium progresses its strategy focusing on a provider and payor model and expanding its revenue base over multiple channels."

The contract for the clinical study is on usual commercial terms and is in addition to the 10-year Master Supply and Development Agreement entered into with AstraZeneca in July 2015.

### **About Adherium (ASX: ADR)**

Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The Company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Adherium's Hailie® solution is designed to help patients achieve better adherence and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user with helpful nudges when



it is time to take doses, and by providing access to usage history to better understand patterns in their Asthma and COPD.

Learn more at [www.adherium.com](http://www.adherium.com)

This ASX announcement was approved and authorised for release by the Board of Adherium.

**Enquiries:** Rick Legleiter  
CEO  
Adherium Limited  
[investors@adherium.com](mailto:investors@adherium.com)